Phaseline

Companies › Aimmune Nestlé Health Science US R&D

Aimmune Nestlé Health Science US R&D: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NHS7108
Recombinant modified triacylglycerol lipase enzyme derived from Bacillus thermoamylovorans
–Phase 2Exocrine Pancreatic Insufficiency (EPI)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07559175NHS7108Phase 2Exocrine Pancreatic Insufficiency (EPI)RespiratoryJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Vicore Pharma SpliSense ReCode Therapeutics Anagram Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.